AI enabled precision diagnostics for heart muscle diseases with hypertrophy

** 心肌病 ** 是一种影响心肌的疾病，可导致心力衰竭和猝死。这种疾病最常见的遗传类型是肥厚型心肌病，它使心脏变厚。在过去的几年里，第一种新药和基因疗法已经开发出来，以更精确地治疗这种疾病。这些都是真实的突破--第一次不仅有希望控制疾病，而且有希望治愈，甚至有可能预防。然而，为了有效治疗这种疾病，医生需要能够更确定地诊断它。目前，医生使用复杂的扫描来诊断患者，但这些扫描没有考虑性别、种族和体型的差异，这可能导致误诊和虐待。伦敦的研究人员开发出人工智能技术，可以比人类专家更准确地测量心脏扫描。通过使用这项技术，他们创造了新的个性化诊断标准，考虑到性别，种族和体型的差异。他们还开发了血液测试来诊断和预测肥厚型心肌病的风险，区分类似的疾病，并帮助医生选择正确的治疗方法。一家名为Mycobile AI Ltd的英国公司，由来自UCL的疾病和AI专家创立，正在使用这项技术来改变心脏病患者的护理。目前，Mycraft AI只专注于一种扫描，即MRI，他们已经帮助了数千名患者，并正在与制药公司合作开发新的治疗方法。通过与UCL，Imperial和LYVA实验室的合作，Mycraft AI旨在将他们的个性化诊断标准应用于全球患者。这将不仅使用MRI，而且还使用超声波（回波扫描）和新的高精度血液测试。通过这样做，他们希望通过提供针对他们特定需求的更好，更早的治疗来改善成千上万患者的生活。这也将简化护理，使社会更健康，更幸福，更富裕。他们计划通过多种渠道向全球医疗保健提供商提供他们的技术，帮助开创心脏病学精确诊断的新时代。

**Cardiomyopathy** is a disease that affects the heart muscle and can cause heart failure and sudden death. The most common genetic type of this disease is called hypertrophic cardiomyopathy, which thickens the heart. In the last few years, the first of new drugs and gene therapies have been developed to treat this disease more precisely. These are real breakthroughs - for the first time promising not just disease control, but cure, and potentially even prevention.However, to treat this disease effectively , doctors need to be able to diagnose it with greater certainty. Currently, doctors use complex scans to diagnose patients, but these scans don't take into account differences in sex, ethnicity, and body size, which can result in misdiagnosis and mistreatment.Researchers in London have developed artificial intelligence technology that can measure heart scans more accurately than human experts. By using this technology, they have created new personalized diagnostic criteria that take into account differences in sex, ethnicity, and body size. They have also developed blood tests to diagnose and predict the risk of hypertrophic cardiomyopathy, distinguish diseases that resemble it and to help doctors choose the right treatment.A UK company called Mycardium AI Ltd, founded by disease and AI experts from UCL, is using this technology to transform heart disease patient care. Currently focusing only on one sort of scan, MRI, they have already helped thousands of patients and are working with drug companies to develop new treatments.In a partnership with UCL, Imperial, and LYVA labs, Mycardium AI aims to apply their personalized diagnostic criteria to patients worldwide. This will be done using not just MRI, but also ultrasound (echo scans) and new highly precise blood tests. By doing so, they hope to improve the lives of tens of thousands of patients by providing better, earlier treatment that targets their specific needs. This will also streamline care and make society healthier, happier, and wealthier. They plan to deliver their technology through multiple channels to healthcare providers worldwide, helping to usher in a new era of precision diagnostics for cardiology.